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Abstract
Tetrathiomolybdate (TM), a drug developed for Wilson's
disease, produces an anti-angiogenic and anti-inflammatory
effect by reducing systemic copper levels. TM therapy has
proved effective in inhibiting the growth of tumors in animal
tumor models and in cancer patients. We have hypothesized
that TM may be used for the therapy of rheumatoid arthritis and
have examined the efficacy of TM on adjuvant-induced arthritis
in the rat, which is a model of acute inflammatory arthritis and
inflammatory cachexia. TM delayed the onset of and suppressed
the severity of clinical arthritis on both paw volume and the
arthritis score. Histological examination demonstrated that TM
significantly reduces the synovial hyperplasia and inflammatory
cell invasion in joint tissues. Interestingly, TM can inhibit the
expression of vascular endothelial growth factor in serum
synovial tissues, especially in endothelial cells and
macrophages. Moreover, the extent of pannus formation, which
leads to bone destruction, is correlated with the content of
vascular endothelial growth factor in the serum. There was no
mortality in TM-treated rat abnormalities. TM also suppressed
inflammatory cachexia. We suggest that copper deficiency
induced by TM is a potent approach both to inhibit the
progression of rheumatoid arthritis with minimal adverse effects
and to improve the well-being of rheumatoid arthritis patients.
Introduction
Rheumatoid arthritis (RA) is a chronic, destructive inflamma-
tory polyarticular joint disease. It is characterized by massive
synovial proliferation and subintimal infiltration of inflammatory
cells, which along with angiogenesis leads to the formation of
a very aggressive tissue called pannus [1,2]. Expansion of the
pannus induces bone erosion and cartilage thinning, leading
to the loss of joint function. The rheumatoid pannus can thus
be considered a local tumor. One of the earliest phenomena
observed in RA is synovial neovascular formation delivering
nutrients and oxygen to this proliferating pannus [3]. It has
been demonstrated that angiogenesis inhibitors can inhibit the
growth of pannus in animal arthritis models [4]. Vascular
endothelial growth factor (VEGF) plays a pivotal role in the
pathogenesis of RA [3,5,6]. Immunohistochemical and in situ
hybridization studies indicate that VEGF is strongly expressed
in subsynovial macrophages, in fibroblasts surrounding micro-
vessels, in vascular smooth muscle cells, and in synoviocytes
[7-9]. VEGF expression is activated at the very early stages of
RA, and it continues throughout the course of the disease
[10,11]. The VEGF level in synovial fluid and tissues correlates
with the clinical severity of RA and with the degree of joint
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destruction [10]. Moreover, VEGF mediates the recruitment,
chemotaxis, and proliferation of osteoclast precursor macro-
phages, leading to bone destruction [11,12].
RA is also characterized by increased production of the inflam-
matory cytokines tumor necrosis factor alpha (TNF-α ) [1], IL-
1α  [13], IL-1β  [1], and fibroblast growth factor (FGF) 1 [14].
TNF-α  appears to be a key mediator in the disease process,
and IL-1β  plays a permissive role by acting to shift the whole-
body protein metabolism towards net catabolism, to elevate
resting energy expenditure, and to increase joint pain and stiff-
ness [15]. Treatment with antibodies against TNF-α , IL-1α ,
and IL-1β  attenuated RA in the experimental mouse model
[16]. FGF-1 is important for the growth of synoviocytes in the
course of RA [17].
Rheumatoid cachexia was first described more than a century
ago [18]. However, it has not been recognized as a common
problem among patients with RA until relatively recently. Rheu-
matoid cachexia leads to muscle weakness, osteoporosis, and
a loss of functional capacity. It also increases susceptibility to
infection [19], and is believed to accelerate morbidity and mor-
tality in RA [15].
Copper is an essential trace element that acts as a cofactor for
a variety of enzymes by virtue of its ability to accept and donate
electrons under physiologic conditions [20]. Additionally, cop-
per ions have recently been demonstrated to be required for
the assembly of multiprotein release complexes in the process
of stress-induced nonclassical release of FGF-1 and IL-1α
[21-23]. These two proteins lack signal sequences in their pri-
mary structures, and cannot be released through the classical
endoplasmic reticulum-Golgi pathway. Their nonclassical
export involves copper-dependent association with a small
calcium-binding protein, S100A13.
Tetrathiomolybdate (TM), which forms a stable tripartite com-
plex with copper and protein, is a copper-lowering agent that
has been evaluated extensively in the treatment of Wilson's
disease [24]. TM treatment decreases serum copper levels
and attenuates angiogenesis and tumor growth in animal
tumor models [25-27]. The hypothesis underlying this
approach is that one or more copper-containing or copper-
binding angiogenic proteins (e.g. VEGF, FGF-1, FGF-2, ang-
iogenin, angiotropin, or others) require higher levels of copper
to be active than are required for basic cellular needs [28]. In
fact, the antitumor activity of TM was evaluated in patients with
advanced kidney cancer in a phase II trial [29].
Alternatively, the in vivo effects of TM may be explained by its
ability to block the release of FGF-1 and IL-1α , both known as
potent proangiogenic and proinflammatory polypeptides.
Indeed, the inhibition of restenosis by TM in the model of dam-
aged rat carotid artery was accompanied by the downregula-
tion of FGF-1 and IL-1α  levels in the vessel wall [22].
Additionally, copper is known to play an important role in the
development and maintenance of the immune system [30].
Some reports revealed that the possibility of inhibiting both
fibrotic response and inflammatory response by copper chela-
tion is due to the suppression of transforming growth factor
beta and TNF-α  production [31,32].
The serum copper level in RA patients has been reported to be
high [33], and the IL-1β  and TNF-α  serum content might cor-
relate with the serum copper level in RA patients [34]. In addi-
tion, D-penicillamine (another anticopper agent) has been
used as the therapy for RA for many years. A previous study
suggested that D-penicillamine might regress rheumatoid syn-
ovial hyperplasia via Fas-mediated apoptosis, but the mecha-
nism of the effect of D-penicillamine is still unknown [35]. In
animal studies, TM is a more fast-acting, more potent, copper
chelating agent than D-penicillamine [36]. We hypothesized
that the anticopper drug TM can be useful for the treatment of
RA through inhibition of proangiogenic and proinflammatory
cytokines. We examined whether TM has the potency to sup-
press chronic inflammation, pannus formation, and angiogen-
esis in the course of adjuvant-induced arthritis (AIA) in female
Lewis rats. We also examined whether copper chelation with
TM reduces the production of VEGF in serum and synovium of
AIA rats and suppresses inflammatory cachexia in AIA rats.
Materials and methods
AIA in rats
Eight-week-old female Lewis rats were obtained from Charles
River Japan (Yokohama, Japan). Complete Freund's adjuvant
was prepared by suspending heat-killed Mycobacterium
butyricum (Difco Laboratories, Detroit, MI, USA) in liquid par-
affin (Merck & Co., Whitehouse Station, NJ, USA) (a kind gift
from Nippon Shinyaku, Kyoto, Japan) at 12 mg/ml. Complete
Freund's adjuvant-induced arthritis was stimulated by injection
of 50 µl Complete Freund's adjuvant emulsion intradermally at
the base of the tail, as described previously [37-39]. This
experimental procedure was designed and carried out accord-
ing to the institutional rules and regulations of the animal
research of Kyoto Prefectural University of Medicine.
Administration of TM
TM treatment commenced 2 weeks before immunization; TM
(10 mg/kg) was given in 3 ml water once daily by means of
intragastric gavage until 10 days after the onset of arthritis.
Deionized water was given to control rats. The animals were
housed four to a cage at 21°C in a 12-hour light/dark cycle.
The rats were killed on day 17 after immunization under
anesthesia with sodium pentobarbital.
Evaluation of arthritis
From day 7 after immunization (onset of arthritis), rats were
examined every 2 days for three clinical parameters: paw vol-
ume, arthritis score, and body weight. The footpad volume was
measured with a water replacement plethysmometer (UnicomAvailable online http://arthritis-research.com/content/7/6/R1174
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Japan, Tokyo, Japan). For clinical evaluation of AIA, the mid-
forepaw, the wrist, the joints of the finger, the midfoot, the
ankle, and the joints of the digits were scored on a 0–4 scale:
0, normal; 1, minimal swelling; 2, medium swelling; 3, severe
swelling; 4, severe and nonweight-bearing arthritis. Each limb
was graded, resulting in a maximal clinical score of 48 per
animal.
Copper status
In the course of TM therapy, the copper status cannot be
assessed by direct measurement of serum copper. The accu-
mulation of a tripartite complex of TM, copper, and albumin
turns over slowly. The serum copper is therefore increased
even though the availability of copper is decreased. Serum
ceruloplasmin is a good surrogate marker of copper status
because the liver secretes this copper-containing protein into
the blood at a rate dependent on copper availability [40].
We monitored the copper status by assaying serum cerulo-
plasmin in blood from the tail vein. The ceruloplasmin measure-
ments were made by nephelometry (differential light scattering
from a colored or turbid case solution with respect to a control
solution) using an automated system and reagents available
commercially (Dade Behring Inc., Deerfield, IL, USA) when
TM-treated rats were immunized.
Histological examination
After euthanasia on day 17, the hindpaws were amputated
above the knee joint and were fixed in 7.4% formaldehyde
solution. The paws were then decalcified, embedded in paraf-
fin, and sectioned in a mid-sagittal plane. The sections of artic-
ulation of the tarsal joints were stained with hematoxylin and
eosin, and were examined microscopically. We also per-
formed the hematoxylin and eosin staining of tissue specimens
of the liver and the kidney.
Two blinded observers evaluated cartilage and bone destruc-
tion by pannus formation, mononuclear cell infiltration, and
vascularity in synovial tissues in each preparation on two sep-
arate occasions, using the following scoring system [41]:
mononuclear cell infiltration (0, no infiltration; 1, mild infiltra-
tion; 2, moderate infiltration; 3, severe infiltration); cartilage
and bone destruction by pannus formation (0, no change; 1,
mild change [pannus invasion within cartilage]; 2, moderate
change [pannus invasion into cartilage/subchondral bone]; 3,
severe change [pannus invasion into the subchondral bone]);
and vascularity (0, almost no blood vessels; 1, a few blood
vessels; 2, some blood vessels; 3, many blood vessels).
Immunostaining
VEGF, CD11b, and von Willebrand factor (vWF) chain anti-
gens were detected by the use of saturating amounts of anti-
bodies against VEGF, CD11b, and vWF in combinations with
immunoperoxidase staining with a Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) according to the manu-
facturer's protocol [14]. The sections were deparaffinized with
xylene and graded ethanol and were immersed in 0.3% perox-
idase in 90% methanol for 45 min in order to exhaust endog-
enous peroxidase. They were preincubated with 0.2% bovine
serum albumin in PBS for 20 min and with diluted normal
horse serum (1:66.7), or normal goat serum (1:66.7) for 30
min followed by incubation with 5 µg/ml anti-VEGF mono-
clonal IgG antibody (sc-7269: Santa Cruz Biotechnology,
Santa Cruz, CA, USA), 10 µg/ml anti-CD11b monoclonal anti-
body (Serotec Ltd, Kidlington, UK), 10 µg/ml anti monoclonal
vWF antibody (Sigma, St Louis, MO, USA), 5 µg/ml purified
rabbit IgG (Vector Laboratories), or 5 µg/ml purified mouse
IgG (Vector Laboratories) for 16 hours in a humid chamber at
4°C. After washing with PBS, the sections were incubated
with biotinylated horse anti-mouse IgG (Vector Laboratories)
or goat anti-rabbit IgG (Vector Laboratories) for 30 min. Then,
after again washing with PBS, the sections were incubated
with avidin and further incubated with biotinylated horseradish
peroxidase complex, each for 45 min. Finally, the sections
were washed with PBS for 10 min and developed by immers-
ing in a solution of 0.05% (w/v) 3,3'-diaminobenzidine tetrahy-
drochloride (Sigma Chemical, St Louis, MO, USA), and 0.01%
hydrogen peroxide in 0.05 M Tris (pH 7.4) for 2 min. The sec-
tions were then counterstained with hematoxylin for 2 min,
dehydrated with graded ethanol and xylene for 1 min, respec-
tively, and finally coverslips were mounted.
For both tissue specimens from TM-treated rats and control
rats, the extent and intensity of staining with anti-VEGF anti-
body in synovial lining cells, macrophages, endothelial cells,
and fibroblasts were graded on a scale of 0–3+ by two
blinded observers on two separate occasions using coded
slides as previously described [37]. A 3+ grade implies maxi-
mally intense staining, whereas 0 implies no staining.
CD11b immunostaining in monocytes was used to evaluate
mononuclear cell infiltration for each of tissue specimens. vWF
immunostaining in endothelial cells was used to evaluate vas-
cularity for each of the tissue specimens.
Measurement of body weight of AIA rats
From day 7 after immunization (onset of arthritis), the body
weight of AIA rats was examined every 2 days. We also meas-
ured body weights of rats at the first administration of TM or of
deionized water. At this initial time point, the differences
between the two groups were not significant. We also meas-
ured body weights of 10-week-old female Lewis rats (n = 10),
which were not immunized, for a period of 14 days as a nega-
tive control.
Measurement of VEGF production in rats
When rats were sacrificed, the serum was collected. We
measured the concentrations of VEGF in the serum using the
VEGF ELISA kit (Biosource International, Camarillo, CA,
USA).Arthritis Research & Therapy    Vol 7 No 6    Omoto et al.
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Statistical analysis
Two-way analysis of variance was used to test the statistical
significance of differences between a TM-treated group and a
control group for the analysis of hindlimb paw volume, body
weight, and clinical score of arthritis. The Mann–Whitney U
test to compare nonparametric data for statistical significance
was applied for the analysis of histological scores. A non-
paired t test was used for the analysis of the serum concentra-
tion of VEGF. The Spearman coefficient of correlation was
used to examine the correlation between the extent of pannus
formation and the VEGF level in the serum.
Results
Oral administration of TTM attenuates AIA
To explore the effect of TM on AIA rats, TM (10 mg/kg) was
administered daily starting from 14 days before immunization.
Inflammatory polyarthritis was induced in all nontreated immu-
nized rats and it occurred on day 8 after immunization (day 7
in Materials and methods). TM administration delayed the
onset and suppressed severity of clinical arthritis comparative
to control rats fed with deionized water, as demonstrated by
both the paw volume (Figs 1a and 2) (P < 0.0001) and the
arthritis score (Fig. 1b) (P < 0.0001). Especially significant TM
effects were observed at days 11–17 after immunization.
These data suggest that oral TM administration inhibits the
onset of and reduces the severity of arthritis in AIA rats. The
body weight of TM-treated rats was significantly increased
compared with control AIA rats (Fig. 1c) (P < 0.0001). We
also measured the body weights of 10-week-old female Lewis
rats (n = 10), which were not immunized, for a period of 14
days. The results show that the body weight of control AIA rats
was significantly decreased compared with that of nonimmu-
nized normal rats, and the body weight gain of TM-treated AIA
rats was almost similar to that of nonimmunized normal rats
(data not shown). These data suggest that oral TM administra-
tion prevents inflammatory body weight loss in AIA rats.
Histological effects of TM in the foot joint of AIA rats
At day 17, histological study of foot joints (shown in Fig. 2) in
TM-treated rats revealed that the infiltration of mononuclear
cells, the formation of pannus in synovial tissues, and the
extent of vascularity were significantly decreased compared
with control rats (P < 0.01; Fig. 3) (data of immunostaining of
CD11b and vWF not shown). These data suggest that TM
exhibits anti-inflammatory and anti-angiogenic effects, and
inhibits the growth of synoviocytes in AIA.
Figure 1
Suppression of clinical arthritis by tetrathiomolybdate (TM) treatment in adjuvant-induced arthritis rats Suppression of clinical arthritis by tetrathiomolybdate (TM) treatment in adjuvant-induced arthritis rats. TM was orally administered daily to female 
Lewis rats, from 2 weeks before immunization to day 17. TM-treated rats, 10 mg/kg/day (n = 8); control rats (n = 8). (a) Arthritis score, (b) paw vol-
ume, and (c) mean body weight were assessed every second day after onset of arthritis.Available online http://arthritis-research.com/content/7/6/R1174
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Figure 2
Morphological features and histopathological aspects of the hindlimb in AIA rats Morphological features and histopathological aspects of the hindlimb in AIA rats. (a) Control rats and (b) rats treated with tetrathiomolybdate (TM). 
Joint swelling, redness, and edema of the foot in AIA was clearly reduced with TM administration at day 17 after immunization. Histopathological 
studies using hematoxylin and eosin staining of the foot joint also revealed (c) a marked decrease of synovial inflammatory cell infiltrate and synovial 
lining hyperplasia compared with (d) control rats. (c), (d) Original magnification × 40. AIA, adjuvant-induced arthritis; MC, monocyte; SL, synovial lin-
ing cell; OC, osteoclast.
Figure 3
Histopathological scores of the hindlimb in AIA rats fed with TM or deionized water Histopathological scores of the hindlimb in AIA rats fed with TM or deionized water. Mononuclear cell infiltration, pannus invasion into the cartilage 
and bone, and vascularity were measured by microscopic examination scores of the sections on two separate occasions (see Histological examina-
tion). We measured the scores of 16 hindlimbs (both hindlimbs of each rat). AIA, adjuvant-induced arthritis; TM, tetrathiomolybdate.Arthritis Research & Therapy    Vol 7 No 6    Omoto et al.
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VEGF expression in synovial tissues in AIA rats
Immunohistochemistry was used to examine the expression
and localization of VEGF in AIA rats (Fig. 4). We found mark-
edly enhanced expression of VEGF in endothelial cells (immu-
nohistochemical score 2.1 ± 0.5), and found moderate
expression in fibroblasts (1.7 ± 0.6) and macrophages (1.6 ±
0.9) of immunized rats. In control nonimmunized rats (n = 6),
the expression of VEGF was 1.1 ± 0.5 in endothelial cells, was
0.6 ± 0.3 in fibroblasts, and was 0.1 ± 0.0 in macrophages. In
TM-treated immunized rats, the localization of VEGF in
synovial tissues was similar to that in control immunized rats.
However, the immunohistochemical score of VEGF in TM-
treated immunized rats in endothelial cells (1.1 ± 0.5, P <
0.01), in macrophages (0.7 ± 0.7, P < 0.01), and in fibroblasts
(1.2 ± 0.5, P < 0.05) was significantly lower than in control
immunized rats. Control immunostaining with normal mouse
serum was completely negative in all animals.
TM effect on VEGF production in AIA rats
To examine the effect of TM upon VEGF production, we meas-
ured the VEGF level in the serum of TM-treated rats and con-
trol AIA rats (Fig. 5a). The production of VEGF in the serum
was significantly suppressed by TM treatment (755.0 ± 354.7
pg/ml versus 1912.5 ± 800.3 pg/ml in TM-untreated animals,
P = 0.0038). Interestingly, the extent of pannus formation sig-
nificantly correlated with the production of VEGF in the serum
(Fig. 5b).
Side effects of oral administration of TM
There was no mortality in TM-treated rats. The liver and kidney
histological examination in TM-treated rats did not show any
abnormalities, and we could not detect any pathological
changes when comparing them with TM-untreated rats.
Discussion
We demonstrated that TM therapy has a strong protective
effect against progression of AIA in rats. Usually AIA is accom-
panied by weight loss because of inflammatory response, but
TM prevents this. TM also significantly reduces the level of
VEGF in the serum and inhibits the expression of VEGF in syn-
ovial tissues, especially in endothelial cells and macrophages.
Joint and bone destruction due to arthritis are markedly sup-
pressed by TM, and the extent of bone destruction is signifi-
cantly correlated with the production of VEGF in the serum.
An increase of serum copper and ceruloplasmin concentra-
tions has been demonstrated in RA patients [34,42]. In RA
these parameters are measures of disease, and they do not
depend on dietary factors [43]. Acute or chronic inflammatory
processes cause an accumulation of zinc and copper in many
organs, particularly in the inflamed areas [44]. Additionally, a
number of biologically active extracellular polypeptides,
including cytokines and angiogenic factors, which participate
in the pathogenesis and development of inflammatory proc-
esses, are known to be involved in trace metal metabolism.
Copper plays an important role in development and mainte-
nance of the immune system [30]. IL-1α  and FGF-1 are Cu2+-
binding proteins. The stress-induced IL-1α  and FGF-1 release
pathways in murine NIH 3T3 cells and human U937 cells are
sensitive to TM treatment [45]. The presence of copper in cell
cultures is essential for T-cell proliferation induced by macro-
phages or by macrophage-mediated cytokines [30]. A recent
study revealed that IL-1β  and TNF-α  levels significantly corre-
late with serum copper concentrations [34]. In our study, in
vivo, copper chelation with TM strongly repressed acute
inflammation and onset of AIA through inhibition of mononu-
clear cell infiltration, and pannus formation.
TM has been shown to be a potent anti-angiogenic and anti-
metastatic compound in tumors. In a phase II clinical trial for
advanced renal cell carcinoma, patients rendered copper defi-
cient with TM therapy had a significantly decreased serum
content of proangiogenic mediators, VEGF, FGF-2, IL-6, and
Figure 4
Immnunostaining for VEGF in synovial tissue in AIA rats Immnunostaining for VEGF in synovial tissue in AIA rats. (a),(c), (e) AIA 
rats treated with deionized water and (b),(d) tetrathiomolybdate (TM). 
Immunohistochemical staining was performed with the Vecto Stain avi-
din–biotin peroxidase complex kit (Vector Laboratories, Burlingame, 
CA, USA). Synovial tissues sections were stained with (a)–(d) mouse 
anti-VEGF monoclonal IgG antibodies (1:200 dilution, in PBS; Santa 
Cruz Biotechnology, Santa Cruz California, USA) and (e) a normal 
mouse IgG (1:200 dilution, in PBS). Positive immunostaining was indi-
cated by brownish deposits. The counterstain was an aqueous solution 
of hematoxylin. (a), (b) Original magnification × 40; (c)–(e) original mag-
nification × 400. AIA, adjuvant-induced arthritis; ET, endothelial cell; 
SL, synovial lining cell.Available online http://arthritis-research.com/content/7/6/R1174
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IL-8 [29]. In RA patients, proangiogenic factors such as VEGF
play an important role in pathological angiogenesis, and the
other factors such as IL-6 and IL-8 are considered to have
additional effects on its development. VEGF is also a key
player in pannus development, acting through the VEGF
receptor I signaling pathway. The blockade of the VEGF
receptor I suppresses joint destruction in the K/BxN model of
RA [46], and serum concentrations of VEGF are elevated in
RA patients and correlate with disease activity [47]. In our
study, the onset of AIA in rats is delayed, and its severity is
suppressed by TM administration through the inhibition of pan-
nus formation and angiogenesis. The anti-arthritic effect of TM
might therefore result from the inhibition of VEGF production
by synovial tissues. We also examined the efficacy of TM
administration starting from day 7 after immunization (the
onset of the disease) for AIA in rats; in this case, TM had only
a mild anti-arthritic effect. Apparently, to efficiently attenuate
arthritis, copper depletion needs to be achieved by the
moment of its onset.
TM was well tolerated in patients with advanced kidney cancer
in a phase II trial, with dose reductions most commonly occur-
ring for grade 3–4 granulocytopenia of short duration not
associated with febrile episodes [29]. The principal features
observed in severe copper deficiency are anemia, neutrope-
nia, and osteoporosis. TM was remarkably nontoxic when cer-
uloplasmin was lowered to 10–20% of baseline levels for up
to 17 months of treatment, and the only drug-related toxicity
observed was mild anemia, which was easily reversible with
adjustment of the TM dose to bring the ceruloplasmin level to
the desired target [40]. But various side effects may occur
when ceruloplasmin is reduced below 5 mg/dl, such as bone
marrow suppression, diarrhea, and arrhythmia. We assayed
the serum ceruloplasmin level as a surrogate marker of copper
status, and kept it in a range between 5 and 10 mg/dl in TM-
treated rats. As the histological examination of the liver and
kidney demonstrated, no significant adverse effects were
observed. This means that the extent of copper chelation in
this study was sufficient and not excessive.
We have demonstrated that TM administration prevents
cachexia, which is associated with RA. It is known that AIA in
rats is a useful model of inflammatory cachexia that mimics the
human pathophysiology in important ways, and is consistent
with cytokine-driven cachexia in chronic inflammatory arthritis
[48]. We found that the body weight of control AIA rats was
significantly decreased compared with that of nonimmunized
normal rats, and the body weight gain of TM-treated AIA rats
was almost similar to that of nonimmunized normal rats. Rheu-
matoid cachexia is characterized by altered energy and protein
metabolism (reduced total energy expenditure, increased rest-
ing energy expenditure, and increased whole-body protein
catabolism) and increased inflammatory cytokine production
[15].
Figure 5
VEGF levels in the serum are correlated with the extent of arthritis in rats VEGF levels in the serum are correlated with the extent of arthritis in rats. (a) VEGF levels in the serum are higher in control rats than in tetrathiomo-
lybdate (TM)-treated rats (* P < 0.01). VEGF was analyzed by ELISA, as described in Materials and methods. Data represent the mean ± standard 
deviation. (b) A significant positive relationship between VEGF levels in the serum and the severity of pannus formation in hindlimbs of adjuvant-
induced arthritis rats, which includes both the control group and the TM-treated group. VEGF, vascular endothelial growth factor.Arthritis Research & Therapy    Vol 7 No 6    Omoto et al.
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Leptin is a peptide hormone-regulating body weight, and it
exhibits a variety of other effects including the regulation of the
endocrine system, reproduction, and immunity [49,50]. The
severity of antigen-induced arthritis is decreased in leptin-defi-
cient ob/ob mice [49]. Furthermore, serum leptin levels in
patients with RA are significantly higher than those in control
patients, and leptin stimulates proinflammatory cytokine pro-
duction in monocytes and macrophages in vitro [51]. Moreo-
ver, it is reported that TM therapy resulted in significantly
reduced body-weight loss caused by bleomycin-induced pul-
monary fibrosis in mice [31].
These findings suggest that copper chelation by TM may not
only suppress joint destruction, but also may influence energy
and protein metabolism in the course of RA through the upreg-
ulation of the adipocytokine leptin.
Conclusion
TM therapy had a strong protective effect against progression
of adjuvant arthritis in rats and inflammatory cachexia with min-
imal adverse effects. TM also significantly reduced the content
of VEGF in the serum and synovial tissues. Joint and bone
destruction due to arthritis was markedly suppressed with TM.
The extent of bone destruction was correlated with the pro-
duction of VEGF in the serum.
TM is a potential therapeutic candidate for the treatment of
angiogenic and inflammatory diseases in which the serum
copper and VEGF levels are elevated. Additionally, the efficacy
of TM against inflammatory cachexia may be useful for improv-
ing the well-being of RA patents.
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